Price Alert

Enliven Therapeutics Inc. (ELVN)

NASDAQ: ELVN · Real-Time Price · USD

19.03

0.46 (2.48%)

At close: Sep 26, 2025, 11:05 AM

2.48% (1D)

Bid	18.94
Market Cap	1.13B
Revenue (ttm)	316K
Net Income (ttm)	-100.22M
EPS (ttm)	-1.92
PE Ratio (ttm)	-9.91
Forward PE	-8.69
Analyst	Buy
Dividends	n/a

Ask	19.04
Volume	90,365
Avg. Volume (20D)	501,257
Open	18.57
Previous Close	18.57
Day's Range	18.28 - 19.07
52-Week Range	13.30 - 30.03
Beta	1.03
Ex-Dividend Date	n/a

About ELVN

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol ELVN

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for ELVN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

3 months ago

+11.44%

Enliven Therapeutics shares are trading higher. Th... Unlock content with Pro Subscription

4 months ago

-10.41%

Enliven Therapeutics shares are trading lower after the company reported worse-than-expected Q1 EPS results.

News

1 week ago · zacks.com

Wall Street Analysts Predict a 106.48% Upside in Enliven Therapeutics, Inc. (ELVN): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 106.5% in Enliven Therapeutics, Inc. (ELVN). While the effectiveness of this highly sought-after metric is ques...

2 weeks ago · zacks.com

Enliven Therapeutics, Inc. (ELVN) Upgraded to Buy: Here's What You Should Know

Enliven Therapeutics, Inc. (ELVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

4 weeks ago · zacks.com

How Much Upside is Left in Enliven Therapeutics, Inc. (ELVN)? Wall Street Analysts Think 102.41%

The consensus price target hints at a 102.4% upside potential for Enliven Therapeutics, Inc. (ELVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend i...

2 months ago · zacks.com

Can Enliven Therapeutics, Inc. (ELVN) Climb 75.66% to Reach the Level Wall Street Analysts Expect?

The consensus price target hints at a 75.7% upside potential for Enliven Therapeutics, Inc. (ELVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in...